Stockreport

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Oculis Holding AG - Ordinary shares  (OCS) 
PDF Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic ma [Read more]